HK1205530A1 - Gene expression and pain - Google Patents

Gene expression and pain

Info

Publication number
HK1205530A1
HK1205530A1 HK15106124.9A HK15106124A HK1205530A1 HK 1205530 A1 HK1205530 A1 HK 1205530A1 HK 15106124 A HK15106124 A HK 15106124A HK 1205530 A1 HK1205530 A1 HK 1205530A1
Authority
HK
Hong Kong
Prior art keywords
pain
gene expression
gene
expression
Prior art date
Application number
HK15106124.9A
Other languages
English (en)
Chinese (zh)
Inventor
Julien Mamet
Original Assignee
Adynxx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx Inc filed Critical Adynxx Inc
Publication of HK1205530A1 publication Critical patent/HK1205530A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15106124.9A 2007-05-11 2015-06-26 Gene expression and pain HK1205530A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91758307P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
HK1205530A1 true HK1205530A1 (en) 2015-12-18

Family

ID=40002879

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106124.9A HK1205530A1 (en) 2007-05-11 2015-06-26 Gene expression and pain

Country Status (14)

Country Link
US (5) US7943591B2 (de)
EP (3) EP2818550B1 (de)
JP (5) JP5646320B2 (de)
AU (1) AU2008251320B2 (de)
CA (1) CA2723672C (de)
DK (1) DK2158316T3 (de)
ES (2) ES2542511T3 (de)
HK (1) HK1205530A1 (de)
HR (1) HRP20150759T1 (de)
HU (1) HUE025701T2 (de)
PL (1) PL2158316T3 (de)
PT (1) PT2158316E (de)
SI (1) SI2158316T1 (de)
WO (1) WO2008141308A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542511T3 (es) 2007-05-11 2015-08-06 Adynxx, Inc. Expresión génica y dolor
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
IN2012DN00720A (de) 2009-07-06 2015-06-19 Ontorii Inc
WO2011029092A1 (en) 2009-09-04 2011-03-10 University Of Miami Klf family members regulate intrinsic axon regeneration ability
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
US20130071444A1 (en) 2011-09-16 2013-03-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Amphiphilic Cationic Polymers and Methods of Use Thereof
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
ES2724851T3 (es) * 2012-05-10 2019-09-16 Adynxx Inc Formulaciones para el suministro de principios activos
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
GB201310853D0 (en) * 2013-06-18 2013-07-31 Ucb Pharma Sa Method
EP3095460A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
EP3626822A1 (de) * 2014-08-15 2020-03-25 Adynxx, Inc. Oligonukleotidköder zur behandlung von schmerz
EP3348637B1 (de) * 2015-09-09 2022-03-09 AnGes, Inc. Chimäres lockmittel
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
WO2024044770A1 (en) * 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
EP0580754A1 (de) * 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynukleotide und oligonukleotide, verwendbar als köder für proteine, die ausgewählt zu definierten dns-sequenzen binden
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
AU7518194A (en) * 1993-07-29 1995-02-28 Regents Of The University Of California, The Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
ATE395065T1 (de) * 1993-10-29 2008-05-15 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
AU3881095A (en) 1994-11-17 1996-06-17 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
WO1996029433A1 (en) 1995-03-23 1996-09-26 Research Foundation Of State University Of New York Rest protein and dna
MX9708663A (es) * 1995-05-11 1998-02-28 Applied Research Systems Inhibidor de actividad il-6.
DK0824918T3 (da) * 1995-05-12 2007-06-04 Anges Mg Inc Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
ATE383172T1 (de) * 1996-05-20 2008-01-15 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1999001155A1 (fr) * 1997-07-04 1999-01-14 Fujisawa Pharmaceutical Co., Ltd. Cephalo-protecteur
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
SK18322000A3 (sk) 1998-06-02 2001-11-06 Glaxo Group Limited Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
US6140128A (en) 1998-12-23 2000-10-31 Genentech, Inc. Preparation of calcium phosphate transfectacons
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6599741B1 (en) * 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) * 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1344536A4 (de) 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd Verfahren zur regulierung der wirkung des expressionsprodukts eines in einen lebenden körper transferierten gens
WO2002066071A2 (en) 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
WO2002070668A2 (en) 2001-03-06 2002-09-12 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (de) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) Promotersequenzen welche spezifisch mit IRF-1 und IRF-2 interagieren
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
EP1496835A4 (de) 2002-02-01 2006-10-18 Omeros Corp Zusammensetzungen und verfahren für die systemische unterdrückung von knorpelabbau
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US20070014840A1 (en) 2002-04-26 2007-01-18 In-Kyu Lee Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
WO2004052401A2 (en) 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
DE10257421A1 (de) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
EP1644532A4 (de) 2003-06-30 2007-11-28 Massachusetts Inst Technology Egr-gene als ziele für die diagnose und behandlung von schizophrenie
WO2005027830A2 (en) * 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
CA2583413A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
US20060189564A1 (en) * 2004-10-22 2006-08-24 Medtronic, Inc. Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain
US8067384B2 (en) * 2004-10-22 2011-11-29 Anges Mg, Inc. Chimera (double) decoy
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) * 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
US7680060B2 (en) * 2005-03-08 2010-03-16 Cisco Technology, Inc. Transferring state information in a network
WO2008105959A2 (en) 2006-10-09 2008-09-04 Neurofluidics, Inc. Cerebrospinal fluid purification system
AU2008242842B2 (en) 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
ES2542511T3 (es) * 2007-05-11 2015-08-06 Adynxx, Inc. Expresión génica y dolor
ES2598556T3 (es) 2010-08-20 2017-01-27 Replicor Inc. Complejos de quelatos de oligonucleótidos
JP2014526882A (ja) 2011-06-21 2014-10-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド 対象中の治療剤の活性を判定するアッセイおよび方法
EP3257505A1 (de) 2011-07-20 2017-12-20 Hospira, Inc. Zusammensetzungen enthaltend diclofenac zur behandlung von postoperativen schmerzen
ES2724851T3 (es) 2012-05-10 2019-09-16 Adynxx Inc Formulaciones para el suministro de principios activos
KR102068109B1 (ko) 2012-05-18 2020-01-21 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체-폴리펩타이드 조성물 및 방법
EP3626822A1 (de) 2014-08-15 2020-03-25 Adynxx, Inc. Oligonukleotidköder zur behandlung von schmerz
US20200017853A1 (en) 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
EP3199635B1 (de) 2019-02-06
EP2818550B1 (de) 2016-12-28
JP5646320B2 (ja) 2014-12-24
ES2542511T3 (es) 2015-08-06
US9290762B2 (en) 2016-03-22
EP2158316B1 (de) 2015-04-15
DK2158316T3 (en) 2015-07-20
US10041069B2 (en) 2018-08-07
EP3199635A1 (de) 2017-08-02
US8741864B2 (en) 2014-06-03
ES2619314T3 (es) 2017-06-26
CA2723672C (en) 2019-09-03
US20120232131A1 (en) 2012-09-13
JP2014198053A (ja) 2014-10-23
JP5890869B2 (ja) 2016-03-22
WO2008141308A3 (en) 2009-03-05
EP2818550A1 (de) 2014-12-31
AU2008251320B2 (en) 2013-12-19
US7943591B2 (en) 2011-05-17
US20160222382A1 (en) 2016-08-04
AU2008251320A1 (en) 2008-11-20
JP6082796B2 (ja) 2017-02-15
JP2017148074A (ja) 2017-08-31
US8093225B2 (en) 2012-01-10
WO2008141308A2 (en) 2008-11-20
PL2158316T3 (pl) 2015-10-30
US20140343132A1 (en) 2014-11-20
EP2158316A2 (de) 2010-03-03
JP2010526541A (ja) 2010-08-05
SI2158316T1 (sl) 2015-08-31
HUE025701T2 (en) 2016-04-28
HRP20150759T1 (hr) 2015-08-14
CA2723672A1 (en) 2008-11-20
JP2016014070A (ja) 2016-01-28
US20080300209A1 (en) 2008-12-04
JP6306075B2 (ja) 2018-04-04
EP2158316A4 (de) 2011-11-09
PT2158316E (pt) 2015-07-20
JP2016117775A (ja) 2016-06-30
US20110166212A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
HK1205530A1 (en) Gene expression and pain
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2069496A4 (de) Verbessertes selex und photoselex
ZA201200161B (en) Aximi-205 pesticidal gene and methods for its use
EP2185692A4 (de) Hco32 und hco27 sowie entsprechende beispiele
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
EP2157919A4 (de) Endoskopische freisetzungsvorrichtungen und verfahren
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
EP2240231A4 (de) Multifunktionskatheter und seine verwendung
EP2518147A4 (de) Diacylglycerolacyltransferasegen und seine verwendung
IL206125A0 (en) Azaindolizines and methods of use
GB0702931D0 (en) Skin application
EP2213675A4 (de) Pyridooxazepinderivat und seine verwendung
PT2154144E (pt) Oligonucleotídeos e utilização dos mesmos
EP2133326A4 (de) Neues pseudoglycolipid und anwendung davon
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0813359D0 (en) Halfin and/or platerfin
GB0707069D0 (en) Methods and uses
EP2041311A4 (de) Varianten des dpyd-gens und ihre verwendung
EP2427766A4 (de) Menschliches fg01-gen und anwendungen dafür
GB0812734D0 (en) MEdical compsoitions and devices
EP2168951A4 (de) Azolylmethylidenhydrazinderivat und seine verwendung
GB0818663D0 (en) Gene regulation and its use in therapy
GB0720675D0 (en) Oligonucleotides and uses thereof
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210518